Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Category: #health  By Pankaj Singh  Date: 2019-10-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatment, adults on the other hand are required to take medication for bleeding. However, various pharmaceutical companies are still focusing on developing an effective treatment that can eliminate ITP in a short span of time.

Principia Biopharma Inc. is one such firm that has made some significant contribution in this field. The company has recently revealed preliminary data from its ongoing Phase 1/2 study of PRN1008, in a highly refractory and treatment-resistant patient population that are suffering from immune thrombocytopenia (ITP). 

Speaking on the development, Dolca Thomas, MD, Chief Medical Officer, Principia, said that the company is thrilled by the data presented and is delighted to see the scientific community recognizing this as a significant new clinical data from its oral BTK inhibitor. 

Thomas added that the company is looking forward towards sharing its findings at the oral presentation in ASH to the global hematology community.

Reportedly, in the preliminary data conducted on 15 patients who had finished a minimum of 12 weeks of therapy, greater response rate of more than 50% was witnessed in both the endpoints. Additionally, PRN1008 is claimed to be well-tolerated in all studies, which showed no episodes of thrombotic or bleeding events.

However, these earlier findings might change as more new patients will be progressed and enrolled in the study. Principia Biopharma is also likely to demonstrate an updated data at the forthcoming ASH (American Society of Hematology) Annual Meeting which will be conducted in December.

Incidentally, Principia Biopharma has also prior made headlines when it announced that it would be appointing former Chief Commercial Officer of Kite Pharma, Shawn Tomasello in its Board of Directors

As per Martin Babler, President and Chief Executive Officer, Principia Biopharma, the company is delighted to welcome Shawn in its Board as she brings in a good track record in commercializing and development of pharmaceutical products.

Source Credit: https://ir.principiabio.com/news-releases/news-release-details/principia-announces-positive-preliminary-data-prn1008-immune



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...